Scleromyxedema

Current Opinion in Rheumatology

Volumn 26, Issue 6, 2014, Pages 658-662

  Hummers, Laura K ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bortezomib; Intravenous immunoglobulin; Mucin; Scleromyxedema; Thalidomide

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN; LENALIDOMIDE; THALIDOMIDE; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SCLERODERMA; SCLEROMYXEDEMA; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; TREATMENT OUTCOME;

BORONIC ACIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PYRAZINES; SCLEROMYXEDEMA; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84927797646     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000118     Document Type: Review

References (41)

1. Rongioletti F. Lichen myxedematosus (papular mucinosis): new concepts and perspectives for an old disease. Semin Cutan Med Surg 2006; 25:100-104.
2. Clark BJ, Mowat A, Fallowfield ME, et al. Papular mucinosis: is the inflammatory cell infiltrate neoplastic? The presence of a monotypic plasma cell population demonstrated by in situ hybridization. Br J Dermatol 1996; 135:467-470.
3. Rongioletti F, MerloG, Cinotti E, et al. Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol 2013; 69:66-72.
4. Gabriel SE, Perry HO, Oleson GB, et al. Scleromyxedema: a scleroderma-like disorder with systemic manifestations. Medicine (Baltimore) 1988; 67:58-65.
5. Godby A, Bergstresser PR, Chaker B, et al. Fatal scleromyxedema: report of a case and review of the literature. J Am Acad Dermatol 1998; 38 (2 Pt 2):289-294.
6. Blum M, Wigley FM, Hummers LK. Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine (Baltimore) 2008; 87:10-20.
7. Verity MA, Toop J, McAdam LP, et al. Scleromyxedema myopathy. Histochemical and electron microscopic observations. Am J Clin Pathol 1978; 69:446-451.
8. Helfrich DJ, Walker ER, Martinez AJ, et al. Scleromyxedema myopathy: case report and review of the literature. Arthritis Rheum 1988; 31:1437-1441.
9. Webster GF, Matsuoka LY, Burchmore D. The association of potentially lethal neurologic syndromes with scleromyxedema (papular mucinosis). J Am Acad Dermatol 1993; 28:105-108.
10. Johkura K, Susuki K, Hasegawa O, et al. Encephalopathy in scleromyxedema. Neurology 1999; 53:1138-1140.
11. Berger JR, Dobbs MR, Terhune MH, et al. The neurologic complications of scleromyxedema. Medicine (Baltimore) 2001; 80:313-319.
12. Harper RA, Rispler J. Lichen myxedematosus serum stimulates human skin fibroblast proliferation. Science 1978; 199:545-547.
13. Yaron M, Yaron I, Yust I, et al. Lichen myxedematosus (scleromyxedema) serum stimulates hyaluronic acid and prostaglandin E production by human fibroblasts. J Rheumatol 1985; 12:171-175.
14. Ferrarini M, Helfrich DJ, Walker ER, et al. Scleromyxedema serum increases proliferation but not the glycosaminoglycan synthesis of dermal fibroblasts. J Rheumatol 1989; 16:837-841.
15. Krebs A, Muller A. Lichen myxedematosus and multiple myeloma type IgG/kappa. Hautarzt 1980; 31:649-653.
16. Muldrow ML, Bailin PL. Scleromyxedema associated with IgG lambda multiple myeloma. Cleve Clin Q 1983; 50:189-195.
17. Dowling JP, Griffiths JD, McLeish JA. Myeloma associated scleromyxedema with extensive involvement of small bowel. Pathology 1991; 23:244-247.
18. Pambor M, Lessel W, Quednow C. Malignant non-Hodgkin lymphoma in the clinical course of Arndt-Gottron scleromyxedema. Dermatol Monatsschr 1983; 169:171-178.
19. Gimenez Garcia R, Garcia SG, Suarez Vilela D, et al. Scleromyxedema associated with non-Hodgkin lymphoma. Int J Dermatol 1989; 28:670-671.
20. Farmer ER, Hambrick GW Jr, Shulman LE. Papular mucinosis. A clinicopathologic study of four patients. Arch Dermatol 1982; 118:9-13.
21. Harris RB, Perry HO, Kyle RA, et al. Treatment of scleromyxedema with melphalan. Arch Dermatol 1979; 115:295-299.
22. Helm F, Helm TN. Iatrogenic myelomonocytic leukemia following melphalan treatment of scleromyxedema. Cutis 1987; 39:219-223.
23. Canueto J, Labrador J, Roman C, et al. The combination of bortezomib and dexamethasone is an efficient therapy for relapsed/refractory scleromyxedema: a rare disease with new clinical insights. Eur J Haematol 2012; 88:450-454.
24. Fett NM, Toporcer MB, Dalmau J, et al. Scleromyxedema and dermato-neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib. Am J Hematol 2011; 86:893-896.
25. Migkou M, Gkotzamanidou M, Terpos E, et al. Response to bortezomib of a patient with scleromyxedema refractory to other therapies. Leuk Res 2011; 35:e209-e211.
26. Yeung CK, Loong F, Kwong YL. Scleromyxoedema due to a plasma cell neoplasm: rapid remission with bortezomib, thalidomide and dexamethasone. Br J Haematol 2012; 157:411.
27. Sansbury JC, Cocuroccia B, Jorizzo JL, et al. Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients. J Am Acad Dermatol 2004; 51:126-131.
28. Caradonna S, Jacobe H. Thalidomide as a potential treatment for scleromyxedema. Arch Dermatol 2004; 140:277-280.
29. Thyssen JP, Zachariae C, Menne T. Successful treatment of scleromyxedema using thalidomide. J Eur Acad Dermatol Venereol 2006; 20:1396-1397.
30. Jacob SE, Fien S, Kerdel FA. Scleromyxedema, a positive effect with thalidomide. Dermatology 2006; 213:150-152.
31. Amini-Adle M, Thieulent N, Dalle S, et al. Scleromyxedema: successful treatment with thalidomide in two patients. Dermatology 2007; 214:58-60.
32. Martins A, Paiva Lopes MJ, Tavares Belo R, et al. Scleromyxedema-thalidomide therapy. J Eur Acad Dermatol Venereol 2008; 22:622-624.
33. Peter LM, Ammoury A, Chiavassa-Gandois H, et al. Scleromyxoedema with associated peripheral neuropathy: successful treatment with thalidomide. Clin Exp Dermatol 2008; 33:606-610.
34. Wu MY, Hong JB, Yang CC, et al. Scleromyxedema with myopathy was successfully treated by thalidomide. J Eur Acad Dermatol Venereol 2009; 23:189-190.
35. Guarenti I, Sebastiani V, Pinto G, et al. Successful treatment of scleromyxedema with oral thalidomide. Int J Dermatol 2013; 52:631-632.
36. Efthimiou P, Blanco M. Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature. Semin Arthritis Rheum 2008; 38:188-194.
37. Dolenc-Voljc M, Jurcic V, Hocevar A, et al. Scleromyxedema with subcutaneous nodules: successful treatment with thalidomide and intravenous immunoglobulin. Case Rep Dermatol 2013; 5:309-315.
38. Brunet-Possenti F, Hermine O, Marinho E, et al. Combination of intravenous immunoglobulins and lenalidomide in the treatment of scleromyxedema. J Am Acad Dermatol 2013; 69:319-320.
39. Caudill L, Howell E. Scleromyxedema: a case clinically and histologically responsive to intravenous immunoglobulin. J Clin Aesthet Dermatol 2014; 7:45-47.
40. Rey JB, Luria RB. Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin. J Am Acad Dermatol 2009; 60:1037-1041.
41. Marshall K, Klepeiss SA, Ioffreda MD, et al. Scleromyxedema presenting with neurologic symptoms: a case report and review of the literature. Cutis 2010; 85:137-140.